Study of cases of abiraterone discontinuation due to toxicity in pre-chemotherapy after 1 year’s experience

Abstract

Abiraterone acetate is a potent and irreversible inhibitor of cytochrome p450 17A1 that suppresses androgen synthesis. It is approved for chemotherapy-naive and docetaxel-treated patients with metastatic castration-resistant prostate cancer. We describe the protocol for use of abiraterone in metastatic castration-resistant prostate cancer chemotherapy naive patients has been implanted in our centre and we review the cases of those patients whose adverse effects have forced the discontinuation of treatment. The side effects fit the safety profile of abiraterone, speed of their appearance and severity indicate that you should perform a thorough follow-up of these patients especially in the early phases of treatment.

Keywords

Abiraterone prostate cancer safety clinical management metastatic castration-resistant prostate cancer

Get full access to this article

View all access options for this article.

References

Crawford

Higano

Shore

et al.

Treating patients with metastatic castration-resistant prostate cancer: a comprehensive review of available therapies. J Urol 2015; 194: 1537–1547.

Ryan

Smith

Fizazi

et al.

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2015; 16: 152–160.

Zytiga: EPAR – Product Information - 10/06/2016 Zytiga - EMEA/H/C/002321, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002321/WC500112858.pdf (accessed 6 September 2016).

Lorente

Mateo

Perez-Lopez

et al.

Sequencing of agents in castration-resistant prostate cancer. Lancet Oncol 2015; 16: e279–e292.

Naranjo

Busto

Sellers

et al.

A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239–245.

Fizazi

Scher

Molina

et al.

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: Final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012; 13: 983–992.

Ryan

Smith

de Bono

et al.

Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368: 138–148.

Mostaghel

. Abiraterone in the treatment of metastatic castration-resistant prostate cancer. Cancer Manag Res 2014; 6: 39–51.

Hoy

. Abiraterone acetate: A review of its use in patients with metastatic castration-resistant prostate cancer. Drugs 2013; 73: 2077–2091.

10.

Abiraterone: Drug Information, In: Post TW (ed.) UpToDate, Waltham, MA, https://www.uptodate.com/contents/abiraterone-drug-information (accessed 6 September 2016).

11.

Perletti

Monti

Marras

et al.

Efficacy and safety of second-line agents for treatment of metastatic castration-resistant prostate cancer progressing after docetaxel. A systematic review and meta-analysis. Arch Ital Urol Androl 2015; 87: 121–129.

12.

Procopio

Grassi

Testa

et al.

Safety of abiraterone acetate in castration-resistant prostate cancer patients with concomitant cardiovascular risk factors. Am J Clin Oncol 2015; 38: 479–482.

13.

Tolcher

Chi

Shore

et al.

Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer. Cancer Chemother Pharmacol 2012; 70: 305–313.

14.

Pia

Vignani

Attard

et al.

Strategies for managing ACTH dependent mineralocorticoid excess induced by abiraterone. Cancer Treat Rev 2013; 39: 966–973.

15.

Verzoni

Grassi

Ratta

et al.

Safety of long-term exposure to abiraterone acetate in patients with castration-resistant prostate cancer and concomitant cardiovascular risk factors. Ther Adv Med Oncol 2016; 8: 323–330.